The firm's financial position appears increasingly vulnerable as total assets contracted from $42.9 million in 2024Q1 to $11.1 million in 2026Q1, while accumulated deficits reached $274.8 million.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 |
|---|
| Total Current Assets | 9.27M | 14.04M | 24.25M | 10.45M | 20.53M | 36.57M | 57.94M | 11.39M | 13.95M | 10.47M | 12.19M | 4.18M | 9.7M | 2.77M | 5.13M | 5.82M | 2.44M | 8.87M | 1.39M | 11.06M | 11.89M | 4.8M | 102.57K |
| Cash & Short-Term Investments | 8.35M | 13.2M | 23.29M | 9.56M | 19.87M | 35.7M | 57.17M | 10.61M | 13.26M | 10.01M | 11.44M | 3.86M | 9.42M | 2.42M | 4.68M | 5.51M | 2.37M | 8.77M | 1.26M | 9.74M | 9.94M | 4.27M | 10.36K |
| Cash Only | 8.35M | 13.2M | 23.29M | 9.56M | 19.87M | 35.7M | 57.17M | 10.61M | 13.26M | 10.01M | 11.44M | 3.86M | 9.42M | 2.42M | 4.68M | 5.51M | 2.37M | 8.77M | 1.26M | 9.74M | 9.94M | 4.27M | 10.36K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.58K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 925.67 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 920.04K | 842.43K | 961.66K | 888.23K | 663.24K | 0 | 0 | 0 | 55K | 55K | 55K | 55K | 55K | 55K | 125.54K | 55K | 555K | 0 | 0 | 1.18M | 1.66M | 196.91K | 79.63K |
| Total Non-Current Assets | 1.85M | 939.86K | 1.22M | 1.62M | 1.06M | 630.35K | 719.56K | 865.14K | 1.1M | 1.93M | 3.13M | 3.42M | 3.72M | 4.05M | 6.35M | 4.75M | 24.11K | 59.45K | 73.8K | 48.16K | 34.69K | 136.77K | 6K |
| Property, Plant & Equipment | 1.82M | 910.08K | 1.19M | 1.59M | 978.98K | 549.13K | 638.35K | 783.92K | 543.34K | 244.71K | 1.44M | 1.73M | 2.03M | 2.36M | 2.65M | 3.04M | 8.76K | 44.1K | 58.45K | 32.81K | 23.81K | 22.61K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.00x | 3.81x | 2.18x | 2.16x | - | - | 0.56x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.68M | 1.68M | 1.68M | 1.68M | 1.68M | 1.68M | 1.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.35K | 15.35K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 29.78K | 29.78K | 29.78K | 29.78K | 81.21K | 81.21K | 81.21K | 81.21K | 558.91K | 11.87K | 11.87K | 11.87K | 11.87K | 11.87K | 2.03M | 27.22K | 0 | 0 | 15.35K | 15.35K | 10.88K | 114.16K | 6K |
| Total Assets | 11.12M | 14.98M | 25.47M | 12.08M | 21.59M | 37.2M | 58.66M | 12.25M | 15.05M | 12.87M | 15.32M | 7.6M | 13.42M | 6.82M | 11.48M | 10.56M | 2.46M | 8.93M | 1.47M | 11.11M | 11.92M | 4.94M | 108.57K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.00x | 0.01x | 0.01x | 0.09x | - | - | 0.00x | 0.05x |
| Asset Growth % | -186.06% | -41.2% | 110.96% | -44.07% | -41.97% | -36.58% | 378.82% | -18.62% | 16.96% | -16.01% | 101.74% | -43.39% | 96.88% | -40.62% | 8.66% | 329.3% | -72.45% | 509.25% | -86.8% | -6.84% | 141.43% | 4448.82% | - |
| Total Current Liabilities | 4.87M | 4.75M | 9.39M | 25.36M | 11.5M | 3.99M | 3.56M | 2.77M | 1.62M | 2.11M | 1.63M | 5.7M | 6.23M | 4.52M | 732.69K | 503.58K | 904.82K | 16.97M | 6.62M | 7.06M | 1.31M | 217.16K | 4.44M |
| Accounts Payable | 4.72M | 1.44M | 4.11M | 5.62M | 2.56M | 1.42M | 1.43M | 1.28M | 1.54M | 1.87M | 1.42M | 0 | 0 | 1.16M | 716.99K | 478.04K | 565.72K | 3.3M | 4.65M | 6.37M | 1.09M | 211.46K | 2.03M |
| Days Payables Outstanding | -14.8K | 2.46K | - | - | - | - | - | 2.46K | 6.85K | 440.95 | 1.45K | - | - | - | - | - | - | - | - | - | - | - | 291.43K |
| Short-Term Debt | 0 | 100.19K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86.59K | 243.59K | 119.92K | 0 | 0 | 0 | 204.8K | 0 | 0 | 0 | 0 | 0 | 2.02M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.33K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 149K | 3.21M | 4.59M | 17.61M | 7.98M | 1.94M | 0 | 990.87K | 76.09K | 243.99K | 127.13K | 5.46M | 2.06M | 0 | 13.3K | 23.3K | 321.58K | 10.49M | 1.72M | 0 | 0 | 5.7K | 397.61K |
| Current Ratio | 1.90x | 2.96x | 2.58x | 0.41x | 1.78x | 9.16x | 16.26x | 4.11x | 8.60x | 4.95x | 7.47x | 0.73x | 1.56x | 0.61x | 7.00x | 11.55x | 2.69x | 0.52x | 0.21x | 1.57x | 9.05x | 22.11x | 0.02x |
| Quick Ratio | 1.90x | 2.96x | 2.58x | 0.41x | 1.78x | 9.16x | 16.26x | 4.11x | 8.60x | 4.95x | 7.47x | 0.73x | 1.56x | 0.61x | 7.00x | 11.55x | 2.69x | 0.52x | 0.21x | 1.57x | 9.05x | 22.11x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.53M | 309.4K | 1.79M | 494K | 552.98K | 166.29K | 301.74K | 421.64K | 171K | 2.21K | 151.83K | 243.53K | 488.98K | 593.23K | 587.1K | 578.47K | 366.67K | 18.86M | 433.33K | 9.92M | 0 | 0 | 13.73K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 86.63K | 330.08K | 450K | 450K | 450K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 2.54M | 309.4K | 409.59K | 494K | 552.98K | 166.29K | 301.74K | 421.64K | 0 | 2.21K | 5.25K | 7.97K | 11.13K | 0 | 1.69K | 4.09K | 6.33K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -124.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 1.38M | 0 | 0 | 0 | 0 | 0 | 171K | 0 | 146.58K | 148.92K | 147.77K | 143.23K | 135.4K | 0 | -6.33K | 18.46M | 0 | 9.92M | 0 | 0 | 1.14K |
| Total Liabilities | 6.4M | 5.06M | 11.18M | 25.85M | 12.05M | 4.16M | 3.86M | 3.19M | 1.79M | 2.12M | 1.78M | 5.95M | 2.67M | 5.12M | 1.32M | 1.08M | 1.25M | 35.83M | 7.05M | 16.98M | 1.31M | 217.16K | 4.46M |
| Total Debt | 1.53M | 409.59K | 494K | 552.98K | 603.83K | 301.74K | 421.64K | 527.53K | 2.21K | 5.25K | 94.57K | 340.65K | 463.31K | 451.69K | 454.09K | 456.33K | 0 | 0 | 0 | 0 | 0 | 0 | 2.02M |
| Net Debt | -6.82M | -12.79M | -22.79M | -9.01M | -19.26M | -35.4M | -56.74M | -10.09M | -13.25M | -10M | -11.35M | -3.52M | -8.96M | -1.97M | -4.22M | -5.05M | -2.37M | -8.77M | -1.26M | -9.74M | -9.94M | -4.27M | 2.01M |
| Debt / Equity | 0.32x | 0.04x | 0.03x | - | 0.06x | 0.01x | 0.01x | 0.06x | 0.00x | 0.00x | 0.01x | 0.21x | 0.04x | 0.27x | 0.04x | 0.05x | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.07x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.31x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | -445.95x | -819.09x | -1196.63x | -10171.50x | -21.66x | -1209.34x | -941.47x | -16.07x | - | - | - | - | - | - | -2.91x |
| Total Equity | 4.72M | 9.92M | 14.29M | -13.78M | 9.54M | 33.05M | 54.79M | 9.06M | 13.26M | 10.75M | 13.54M | 1.65M | 10.75M | 1.7M | 10.16M | 9.48M | 1.21M | -26.9M | -5.58M | -5.87M | 10.61M | 4.72M | -4.35M |
| Equity Growth % | -157.35% | -30.61% | 203.76% | -244.48% | -71.14% | -39.69% | 504.84% | -31.68% | 23.31% | -20.57% | 720.7% | -84.65% | 532.28% | -83.27% | 7.14% | 685.77% | 104.49% | -381.61% | 4.87% | -155.33% | 124.71% | 208.57% | - |
| Book Value per Share | 1.11 | 3.80 | 11.55 | -33.82 | 40.54 | 178.57 | 829.69 | 354.12 | 1343.15 | 2299.44 | 9305.75 | 6329.37 | 70194.33 | 18244.93 | 148221.21 | 237433.61 | - | - | - | - | - | - | -962872.70 |
| Total Shareholders' Equity | 4.72M | 9.92M | 14.29M | -13.78M | 9.54M | 33.05M | 54.79M | 9.06M | 13.26M | 10.75M | 13.54M | 1.65M | 10.75M | 1.7M | 10.16M | 9.48M | 1.21M | -26.9M | -5.58M | -5.87M | 10.61M | 4.72M | -4.35M |
| Common Stock | 42 | 42 | 461 | 207 | 94 | 611 | 454 | 94 | 47 | 167 | 104 | 9 | 76 | 574 | 464 | 369 | 4.53K | 697 | 440 | 392 | 392 | 279 | 44 |
| Retained Earnings | -274.79M | -269.13M | -247.34M | -202.76M | -159.99M | -150.9M | -126.78M | -111.68M | -97.59M | -84.35M | -70.79M | -64.61M | -59.17M | -51.06M | -40.28M | -31.48M | -73.98M | -76.07M | -59.69M | -43.24M | -23.68M | -15.4M | -12.35M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.96K |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.46M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital structure dilution risk
As reported in recent financial filings, Cellectar's total assets have declined from a peak of $42.9 million in 2024Q1 to $11.1 million in 2026Q1, reflecting a rapid consumption of resources to fund clinical development without a corresponding replenishment from commercial revenue streams.
The consistent downward trend in total assets suggests that the company is operating in a capital-constrained environment where liquidity is prioritized for trial execution over balance sheet expansion. Investors should monitor whether this trajectory necessitates further dilutive financing to maintain the current clinical development pace.
Based on the most recent quarterly data, Cellectar's cash position has dwindled to $8.3 million as of 2026Q1, a significant reduction from the $40.0 million reported in 2024Q1, which underscores the company's ongoing reliance on external capital to sustain its research-heavy operational model.
While the current ratio of 1.90 suggests a temporary ability to cover short-term obligations, the absolute cash level appears insufficient for long-term clinical and commercialization requirements. This liquidity profile indicates that the company remains highly sensitive to capital market conditions and potential financing delays.
According to historical balance sheet data, the company's equity base has been severely impacted by accumulated deficits, which reached $274.8 million by 2026Q1, highlighting the substantial capital destruction inherent in the firm's long-term pursuit of its proprietary PDC platform.
The erosion of equity, punctuated by a negative equity position in 2023Q4, suggests that the company's survival is heavily dependent on periodic equity issuances. This pattern of dilution warrants close investigation by investors, as it directly impacts the potential for future per-share value creation.
As indicated by the company's financial disclosures, the presence of $1.5 million in total debt as of 2026Q1, while modest, introduces a layer of fixed obligations that complicates the firm's already precarious liquidity position during this critical pre-commercial phase of development.
Although the debt-to-equity ratio of 0.32 appears manageable, the lack of recurring revenue means that even minor debt service requirements could exacerbate the existing cash burn. Investors should remain cautious regarding the potential for restrictive covenants or further dilution if the company seeks to restructure these obligations.
Quick answers to the most common questions about buying CLRB stock.
As of 2025, Cellectar Biosciences, Inc. (CLRB) had total assets of $15.0M including $14.0M in current assets.
Cellectar Biosciences, Inc. (CLRB) carries total debt of $0.4M, offset by $13.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Cellectar Biosciences, Inc. (CLRB) has total shareholders' equity (book value) of $9.9M ($3.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Cellectar Biosciences, Inc. (CLRB) reported a current ratio of 2.96x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.